Table 3.
Highly Rigid and Slowed Patients | Less Rigid and Slowed Patients | Comparison | FDR-corr. P-value | |
---|---|---|---|---|
N | 42 | 29 | — | |
Age in years | 37.3 ± 14.4 | 34.6 ± 11.0 | F(1, 69) = 0.8, P = .388 | .466 |
Gender | 21M | 15M | X 2 (1, N = 71) = 0.02, P = .886 | .997 |
Education in years | 13.0 ± 2.4 | 13.0 ± 2.4 | F(1, 69) =.001, P = .977 | .977 |
Duration of illness in years | 12.6 ± 11.4 | 8.0 ± 7.9 | F(1, 69) = 3.5, P = .066 | .108 |
Nr. of episodes | 6.2 ± 5.4 | 3.5 ± 2.6 | F(1, 69) = 6.2, P = .015 | .030* |
SRRS total | 26.3 ± 6.7 | 22.0 ± 5.0 | F(1, 69) = 8.7, P = .004 | .013* |
PANSS Total | 87.2 ± 21.6 | 75.7 ± 12.2 | F(1, 69) = 6.7, P = .012 | .026* |
PANSS Positive | 17.6 ± 6.6 | 15.0 ± 4.1 | F(1, 69) = 3.5, P = .066 | .100 |
PANSS Negative | 26.0 ± 7.2 | 22.2 ± 4.9 | F(1, 69) = 6.2, P =.015 | .027* |
Medication OLZ eq. in mg | 17.7 ± 11.7 | 15.3 ± 9.7 | F(1, 69) = 0.8, P = .374 | .481 |
UPDRS | 25.4 ± 12.1 | 16.9 ± 11.7 | F(1, 69) = 8.7, P = .004 | .015* |
BFCRS | 5.9 ± 4.9 | 5.2 ± 4.3 | F(1, 69) = 2.2, P = .146 | .203 |
mSRRS | 11.5 ± 3.1 | 9.6 ± 2.9 | F(1, 69) = 6.8, P = .011 | .029* |
IPAQ | 1400.7 ± 2376.3 | 1382.0 ± 2324.5 | F(1, 69) = 0.001, P = .974 | >.9 |
Actigraphy | 11313.6 ± 3584.4 | 15552.5 ± 5076.9 | F(1, 69) = 17.0, P < .001 | <.001*** |
Gait velocity | 94.6 ± 20.1 | 113.6 ± 19.9 | F(1, 69) = 15.5, P < .001 | <.001*** |
CR dominant hand | 8.6 ± 2.4 | 14.5 ± 1.8 | F(1, 69) = 125.9, P < .001 | <.001*** |
CR non-dominant hand | 7.9 ± 2.4 | 12.2 ± 2.1 | F(1, 69) = 62.1, P < .001 | <.001*** |
Note: Displayed are mean ± sd of demographic and clinical variables for each cluster within the PS group. Sd, Standard deviation; SRRS, Salpêtrière Retardation Rating Scale; PANSS, Positive And Negative Syndrome Scale; OLZ eq., Olanzapine-equivalent (mg/day); UPDRS, Unified Parkinson Disease Rating Scale Part III; BFCRS, Bush-Francis Catatonia Rating Scale; mSRRS, motor score of SRRS; IPAQ, International Physical Activity Questionnaire; CR, Coin rotation task; M, male.